Click here to view the printer friendly version of this press release
"The MRX technology may have advantages for patient care compared to PET, CT or MRI methods and we are looking forward to working with Senior Scientific to investigate the diagnostic applications of this technology for patients."
NEW YORK -- Manhattan Scientifics, Inc. announced today that its wholly-owned subsidiary Senior Scientific, LLC, which is developing a platform for the early detection of cancer and other human diseases, has established a research collaboration with Weill Cornell Medicine. For the alliance, the company will bring its magnetic relaxometry technology to Weill Cornell Medicine, where scientists will investigate the use of molecularly targeted nanoparticles to non-invasively detect and diagnose prostate cancers.
“We have extensive experience in targeting radionuclides to cancer for imaging and therapy using antibodies and small molecules,” said John Babich, Ph.D., Professor of Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. “This collaboration enables us to leverage our expertise in prostate cancer targeting to explore Senior Scientific’s non-radioactive magnetic nanoparticle platform for early detection of cancer.”
Gary Dorfman, M.D., Vice Chairman for Research at the Weill Cornell Medicine Department of Radiology and Professor of Radiology added, “The MRX technology may have advantages for patient care compared to PET, CT or MRI methods and we are looking forward to working with Senior Scientific to investigate the diagnostic applications of this technology for patients.”
“I am extremely pleased we will be working with Dr. Babich and Weill Cornell Medicine,” said Bob Proulx, President and COO of Senior Scientific. “There are approximately 1 million prostate biopsies done in the U.S. annually. We believe our technology could significantly improve the way prostate cancer is diagnosed and Weill Cornell Medicine has the expertise to help us.”
On January 13, 2016 the company announced it would be working with the University of Michigan Medical School on a breast cancer program, adding to its existing ovarian cancer program with the MD Anderson Cancer Center. With the addition of Weill Cornell Medicine focusing on prostate cancer, the company has engaged with three pre-eminent U.S. cancer institutes to develop commercial applications of its magnetic relaxometry platform. Each of the three institutions will have our MRX technology on-site, enabling them to undertake the pre-clinical animal model studies necessary in anticipation of first in human testing.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.